-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMATICS demonstrated the clinical activity of IMA402 PRAME bispecific therapy and IMA203CD8 PRAME cell therapy in advanced solid tumors through two oral presentations at the 2026 ESMO annual meeting.

Zhitongcaijing·10/24/2026 06:33:01
Listen to the news
IMMATICS demonstrated the clinical activity of IMA402 PRAME bispecific therapy and IMA203CD8 PRAME cell therapy in advanced solid tumors through two oral presentations at the 2026 ESMO annual meeting.